Between 2017 and 2023, 39 patients with advanced/metastatic HER2-negative unresectable gastric/GEJ adenocarcinoma were enrolled in 6 BIG10 centers to receive FOLFOX-A. The gene discussed is ERBB2; the disease is gastroesophageal junction adenocarcinoma.